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Background: Delta-like ligand 4 (DLL4)-Notch signaling plays a key role in tumor neovascular development
and angiogenesis during tumor growth. The clinical significance of DLL4 expression in gastric cancer has not
been clarified.
Methods: Gastric cancer cell lines and 180 gastric cancer patients were enrolled. DLL4 expression in gastric cancer
cells and stroma was identified and evaluated immunohistochemically. The association between DLL4 and
clinicopathological factors was also assessed.
Results: DLL4 expression was identified in the cellular membrane and cytoplasm of gastric cancer cells by
immunoblotting and immunohistochemical staining. DLL4 positivity in cancer cells and stroma was found in 88 (48%)
and 41 (22%) of the 180 gastric cancer patients respectively. Both cancer and stromal DLL4 expression significantly
correlated with more advanced tumor depth, nodal involvement, and lymphatic and venous invasion. A strongly
positive association between cancerous and stromal DLL4 expression was identified (p < 0.01). Both cancerous and
stromal DLL4 expression were prognostic markers in gastric cancer as determined by univariate analysis.
Conclusions: Cancerous and stromal DLL4 expression was found in 48% and 22% in gastric cancer, and significantly
affected postoperative clinical outcomes. Cancerous and stromal DLL4 expression may be an effective target of anti-
DLL4 treatment in gastric cancer.
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Gastric cancer is one of the major causes of cancer-
related deaths worldwide, especially in East Asia [1-3].
When gastric cancer is diagnosed and treated in the
early stages, the prognosis is good. However, some
patients have an unfavorable postoperative outcome,
despite receiving curative surgery. In addition, gastric
cancer patients with distant metastases cannot undergo
curative surgery. The recent development of novel anti-
cancer agents in unresectable gastrointestinal cancer has
improved clinical outcomes. Antiangiogenetic agents are
promising for treating advanced, refractory tumors. As
angiogenesis directly affects tumor growth and metasta-
sis, it may be an important target for control of tumor* Correspondence: suishigami@hotmail.com
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reproduction in any medium, provided the orprogression [4,5]. Antiangiogenic agents such as bevaci-
zumab, which target the vascular endothelial growth
factor (VEGF) pathway and inhibit angiogenesis, are
promising for the treatment of multiple cancers, inclu-
ding advanced and recurrent gastric cancer. In clinical
trials, these anti-VEGF agents have been shown to prevent
tumor progression and improve overall survival in colorec-
tal, breast, and lung cancer [6-8], as well as advanced gastric
cancer [9,10]. Currently, a promising antiangiogenetic ther-
apy that is unrelated to VEGF-VEGF receptor (VEGFR)
signaling has been demonstrated for bevacizumab-refrac-
tory cancer.
The Notch receptors (Notch-1, -2, -3, -4) and their li-
gands (Delta-like ligands (DLL)-1, -2, -3, -4, and Jagged-1
and Jagged-2) are critically involved in tumor neovascu-
larity. In particular, it has been elucidated that the Notch
Delta-like ligand 4 (DLL4) regulates tumor angiogenesisl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 DLL4 expression in brain tissue. DLL4 expression was
identified in the brain tissue as a positive control of DLL4.
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[12,13]. Troise et al. reported that blocking DLL4 –Notch
signaling caused nonproductive angiogenesis of tumor
vessels, and drastic shrinkage of tumors in mouse models
[14,15]. Moreover, a soluble form of DLL4 blocked tumor
growth in both bevacizumab-sensitive and bevacizumab-
resistant tumors by disrupting vascular function. Recent
studies have demonstrated that DLL4 expression can be
found not only in peritumoral tissues, but also in the
tumor cell itself [16,17]. However, there is little published
data examining DLL4 expression in gastric cancer. We
used immunohistochemistry to evaluate DLL4 expression
of cancer cells and stroma in gastric cancer, speculating
upon the clinical impact of this expression profile.
Materials and methods
180 gastric cancer patients (128 men, mean age 65 –
range 41–85) who underwent gastrectomy at Kagoshima
University Hospital between 2001 and 2004 were enrolled.
None of the patients received preoperative chemotherapy.
All patients underwent R0 resection with greater than D1
lymph node dissection. Clinical factors were assessed by
the Japanese Classification of Gastric Carcinoma [18].
Sample collection and processing are described in greater
detail in the online supplemental data. Written informed
consent was obtained from all patients and the study was
approved by our institutional ethics committee. This
investigation conformed to the principles outlined in the
Declaration of Helsinki.
Immunohistochemistry
Paraffin-embedded sections (4 μm), including tumor
nests were obtained. Sections were deparaffinized and
soaked in PBS prior to immunohistochemical analysis.
Sections were also soaked in 3% H2O2 for 30 minutes in
order to block endogenous tissue peroxidase, followed
by treatment with bovine serum for 30 minutes in order
to reduce nonspecific binding. The DLL4 antibody
(rabbit polyclonal; ab103469; Abcam) was diluted to
1:200, and incubated at room temperature for 12 hours.
Sections were rinsed in PBS and visualized by standard
techniques for labeled avidin-biotin immunoperoxidase
staining. Then, DLL4 was visualized using a DAB Sub-
strate Kit. The slides were briefly counterstained with
hematoxylin and mounted aqueously. Human brain
tissue was used as a positive control for DLL4 expres-
sion (Figure 1). DLL4 positivity of four gastric cancer
cell lines was examined by the same procedures of
paraffin-embedded tissue without deparaffinization.
Detection of DLL4 expression in gastric cancer cell lines
by western blot analysis
Gastric carcinoma cell lines, MKN28, MNK45, KATO-
III, and NUGC4 were purchased from the JapanesePhysical and Chemical Institute, Tokyo, Japan. They
were maintained in RPMI 1640 supplemented with 10%
fetal bovine serum (FBS), 100 units/ml penicillin, and
100 μg/ml streptomycin at 37°C in a cell incubator. All
cells were harvested by centrifugation, rinsed with phos-
phate buffered saline (PBS), and subjected to total pro-
tein extraction in an immunoprecipitation assay buffer
lysis buffer. The separation of nuclear extract and cyto-
plasmic fraction was performed by a Nuclear/Cytosol
Fraction Kit (K266-25 BioVison, USA). Cytoplasmic and
nucleus DLL4 expression were extracted to facilitate
Western blot.
Western blot analysis of DLL4 of gastric cancer cell
lines was performed. Denatured proteins extracted from
the nucleus and cytoplasm were separated on an SDS-
polyacrylamide gel and transferred to Hybond mem-
brane, which was then blocked overnight in 5% skimmed
milk in TBS. For immunoblotting, the membrane was
incubated for 15 minutes with mouse antibody against
DLL4 (1:2000). Then, it was rinsed by TBST and incu-
bated with anti-house IgG conjugated to horseradish
peroxidase for 15 minutes. Bands were visualized with
X-ray film (Fuji, Japan) by ECL-Plus detection reagents.
After that, the membrane was washed with WB Strip-
ping Solution (Nakarai, Tokyo, Japan) for 15 minutes
and treated as described above except anti-β-actin
antibody (sc-47778, Santa Cruz, 1:1000) as the internal
control.
Evaluation of DLL4 expression of cancer cells and stroma
in gastric cancer
DLL4 expression in cancer cell membranes was evaluated,
and averaged in ten different high power magnified fields
(× 400). DLL4 expression was identified in the cytoplasm
and cellular membrane of cancer cells (Figure 2), and in
the stromal cells (Figure 3). Ten representative tissue
Figure 3 DLL4 expression in brain and stromal cells of gastric
cancer. DLL4 positive infiltrative cells were identified in cancer
stroma (yellow arrow).
Figure 2 DLL4 expression in gastric cancer cells. Right: DLL4 expression was identified in the cellular membrane of gastric cancer cells. DLL
positivity was found in the cytoplasm and cellular membrane of gastric cancer (yellow arrow). Left: DLL4 expression was not found in gastric
cancer (negative control).
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percentage of DLL4 positive cancer cells was scored,
averaged, and scored semiquantitatively. All immuno-
stained slides were evaluated by two independent observers
(SI and AT), who were unaware of the clinical data and
disease outcome. If more than 10% of dominant staining
intensity in tumor cells or stromal cells was identified, the
patients were regarded as DLL4 positive. After evaluation,
patients were divided into two groups according to DLL4
expression positivity. Clinicopathological factors of gastric
cancer were assessed according to the General Rules of
Gastric Cancer in Japan [18].
Statistical analysis
Statistical analysis of clinical features was performed
using the χ2-test. Survival curves were constructed using
the Kaplan-Meier method, and survival differences were
analyzed by the generalized Wilcoxon test. Multivariate
analysis was performed to determine prognostic factors.
A p-value of less than 0.05 was considered to be statisti-
cally significant.
Results
DLL4 expression in gastric cancer tissues
DLL4 positivity was identified in brain tissue as a posi-
tive control of DLL4 (Figure 1). DLL4 expression was
primarily identified in the membranes and cytoplasm of
cancer cells, regardless of tumor histology (Figure 2), as
well as infiltrative cells in cancer stroma (Figure 3). 88
(49%) patients were classified as DLL4 positive (10% of
DLL4 positive) group in cell lines; 41 (23%) were positive
in the stroma.
DLL4 expression in gastric carcinoma cell lines
Immunohistochemical staining showed DLL4 expression
in cytoplasm of the four gastric cancer cell lines (Figure 4).
Cell lysates extracted separately from the nucleus and
cytoplasm in the gastric cancer cell lines were loaded andprobed with anti-DLL4 antibody. DLL4 protein was
identified in cytoplasm of the all gastric cancer cell lines,
but not in the nucleus (Figure 5).
Clinicopathological features of DLL4-positive group
Clinicopathologic features of DLL4-positive gastric
cancers were assessed. The DLL4-positive group had a
greater depth of tumor invasion (p < 0.01, p < 0.01), more
lymph node metastases (p < 0.01, p < 0.05), and signifi-
cantly more venous (p < 0.05, n.s.) and lymphatic invasion
(p < 0.01, p < 0.01 respectively) in not only the cancer cell
but also stroma (Table 1, Table 2). However, there was no
significant difference in other clinical factors.
Prognostic impact of DLL4 positivity in gastric cancer
Overall surival of gastric cancer in the absence or pres-
ence of DLL4 expression were evaluated by univariate
and multivariate analyses. The DLL4-positive cancer
Table 1 Association between cancerous DLL4 expression
and clinical factors in 180 gastric cancer
Clinical (n) DLL4 DLL4 p value
Figure 4 DLL4 expression in gastric cancer cell lines. DLL4 expression was identified in the cellular membrane and cytoplasm of gastric cancer cells.
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negative group (p < 0.01; Figure 6). Moreover, the DLL4-
positive stroma group also had a significantly poorer
survival than negative group (p = 0.03; Figure 7). By
univariate analysis, tumor depth, nodal involvement,
lymphatic invasion, and DLL4 positivity were found to
be significant prognostic markers. However, multivariate
analysis did not demonstrate DLL4 to be an independent
prognostic marker for survival (Table 3).Figure 5 DLL4 protein detection in gastric cancer cell lines by
Western blot analysis. DLL4 was detected in the cytoplasm of
gastric cancer cell but not the nucleus in four gastric cancer
cell lines.Discussion
Previously, expression in cancerous tissue was thought to
be limited to the endothelial cells of peritumoral vessels.
However, recent reports have shown a strong association
of DLL4 expression in the cellular membrane of tumorpositive negative
Factors (n = 88) (n = 92)
Sex Male 128 62 66
Female 52 26 26 n.s.
Age 64.2 66.1 n.s.
T factor T1 72 11 61
T2 54 41 13
T3 44 28 16 p < 0.01
T4 10 8 2
N factor N0 93 24 69
N+ 87 64 23 p < 0.01
Lymphatic
invasion
No 78 18 60
Yes 102 70 32 p < 0.01
Venous invasion No 102 31 71
Yes 78 57 21 p < 0.05
Histology Differentiated 98 47 51
Undifferentiated 82 41 41 n.s.
Figure 7 Overall survival of 180 gastric cancer patients
according to DLL4 expression in cancer stroma. DLL4-positive
patients in cancer stroma had significantly poorer survival than
DLL4-negative patients (p = 0.03).
Table 2 Association between stromal DLL4 expression






Factors (n = 41) (n = 139)
Sex Male 128 28 100
Female 52 13 39 n.s.
Age 63.1 65.7 n.s.
T factor T1 72 6 66
T2 54 14 40
T3 44 17 27 p < 0.01
T4 10 4 6
N factor N0 93 15 79 p < 0.01
N+ 87 26 60
Lymphatic
invasion
No 78 10 68 p < 0.01
Yes 102 31 71
Venous invasion No 102 14 88
Yes 78 37 51 n.s.
Histology Differentiated 98 23 75
Undifferentiated 82 18 64 n.s.
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evaluate DLL4 function, its expression must be examined
in both the peritumoral vasculature and cancer cells.
In the current study, cancerous and stromal DLL4
expression were found in 49% and 23% of gastric cancer
patients, which lower than that of colorectal cancer [16].
Moreover, stromal DLL4 expression was not as remar-
kable as previously reported in breast cancer [22];
therefore, the pattern of DLL4 expression in gastric
cancer may be different from that of breast cancer.
Experimentally, DLL4 expression in cancer cells has
been previously analyzed. Li et al. showed that DLL4Figure 6 Overall survival of 180 gastric cancer patients
according to DLL4 expression in cancer cell. DLL4-positive
patients had significantly poorer survival than DLL4-negative
patients (p < 0.01).was upregulated in human glioblastoma [23]; DLL4
expression in tumor cells activated Notch signaling in
endothelial cells; in addition, DLL4 overexpression in
glioma cells led to tumor proliferation, angiogenesis, me-
tastasis, and resistance to hormonal and chemotherapy.
The activated Notch1 signal pathway has been shown to
be involved with gastric cancer progression. Yeh et al.
showed that activation of Notch1 receptor promoted
colony forming ability and tumor growth of cell lines in
gastric cancer [24]. Thus, DLL4 expression in the tumor
cells was functionally active, and appears to be consis-
tent with our clinical data.
In our study, DLL4-positive cancer had more lymph
node metastases and severe lymphatic invasion. Moreover,
stromal DLL4 expression also correlated with tumor
spread. We found a significant correlation between cance-
rous and stromal DLL4 expression; thus, DLL4 may be
associated with lymphatic metastasis, consistent with what
has been shown in other cancers. Jubb et al. investigated
DLL4 expression in metastatic breast cancer after VEGF
treatment, and found anti-VEGF agents to be efficacious
in treating DLL4-positive cancers [22] – suggesting DLL4Table 3 Univariate and multivariate analysis of survival
with clinical factors including DLL4 expression
Factors Univariate Multivariate
p value p value hazard ratio 95% CI
Cancerous DLL4 <0.01 =0.11
Stromal DLL4 <0.05 =0.22
Depth of invasion <0.01 <0.01 0.35 0.16–0.72
Nodal involvement <0.01 <0.01 0.09 0.02–0.47
Lymphatic invasion <0.05 =0.97
Venous invasion <0.05 =0.
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Patel et al. showed that DLL4 was closely associated with
vascular differentiation in bladder cancer; DLL4 appeared
to be a novel target for antiangiogenic treatment in this
scenario as well [25,26]. For tumors in which anti-VEGF
treatment is less effective, Nogueira et al. suggested
that blocking DLL4 signaling might be a promising
strategy [15].
As a prognostic marker, DLL4 positivity contributed to
poor clinical outcomes in gastric cancer, which was simi-
lar to reports by Jubb et al. [17]. By multivariate analysis,
DLL4 was not found to be an independent prognostic
marker, which may be influenced by the strong associ-
ation with lymph node metastasis. Interestingly, DLL4
expression in other cancers is not always associated with
a poor clinical prognosis. For example, Donnem et al.
demonstrated that DLL4 positivity was a good prognos-
tic marker in lung adenocarcinoma [27], different from
our results. Organ specificity in the evaluation of DLL4
expression of the tumor tissues should be considered.
Conclusions
In conclusions, cancerous and stromal DLL4 expression
may be one of the angiogenesis-related prognostic
markers in gastric cancer. Since this protein plays a key
role in angiogenesis, future studies are required to deter-
mine if antiangiogenic therapy will be useful in DLL4-
expressing gastric cancer. Cancerous and stromal DLL4
expression may be a good target for anti-DLL4 therapy in
gastric cancer.
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